(2R)-4-Bromo-1,2-O-isopropylidenebutane-1,2-diol | 96392-13-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R)-4-Bromo-1,2-O-isopropylidenebutane-1,2-diol
• 英文别名: (R)-4-(2-bromoethyl)-2,2-dimethyl-1,3-dioxolane；(4R)-4-(2-bromoethyl)-2,2-dimethyl-1,3-dioxolane
• CAS: 96392-13-1
• 化学式: C₇H₁₃BrO₂
• 分子量: 209.083
• InChiKey: SCINDQADIBQHKD-ZCFIWIBFSA-N

物化性质

• 沸点：
  214.0±15.0 °C(Predicted)
• 密度：
  1.306±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2R)-4-Bromo-1,2-O-isopropylidenebutane-1,2-diol 在 sodium hydroxide 、 lithium aluminium tetrahydride 作用下， 以 乙醚 、 水 、 二甲基亚砜 为溶剂， 生成 2,2-dimethyl-4-(3-hydroxypropyl)-1,3-dioxolane
  参考文献：
  名称：

  An enantiomerically pure epoxyorganolithium reagent for the synthesis of oligo(tetrahydrofurans) by an epoxide-cascade reaction

  摘要：

  Enantiomerically pure oligo(tetrahydrofurans) 17 and 18 have been prepared using an epoxide cascade reaction. The polyepoxide precursors 13 and 14 were synthesized using the enantiomerically pure epoxyorganolithium reagent 3. Thus, addition of 3 to the THF aldehyde 11 gave alcohol 12 with a high Cram selectivity of 95:5.

  DOI：

  10.1016/s0040-4039(00)78360-2
• 作为产物：
  描述：

  (R)-4-(2-羟乙基)-2,2-二甲基-1,3-二氧戊环 在 甲基磺酰氯 、 三乙胺 、 lithium bromide 作用下， 以 四氢呋喃 为溶剂， 反应 21.5h， 以80%的产率得到(2R)-4-Bromo-1,2-O-isopropylidenebutane-1,2-diol
  参考文献：
  名称：

  Nitric oxide enhancing diuretic compounds, compositions and methods of use

  摘要：

  该发明描述了包含至少一种增强一氧化氮利尿化合物或其药用盐的新型组合物和试剂盒，以及可选地，至少一种增强一氧化氮化合物和/或至少一种治疗剂的试剂盒。该发明还提供了以下方法：(a)治疗由过多水分和/或电解贮留引起的症状；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)高脂血症。增强一氧化氮利尿化合物包括至少一种增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点与利尿化合物连接，连接通过不能水解的键或基团。

  公开号：

  US20060189603A1

文献信息

• [EN] ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS<br/>[FR] ARYLOXYACÉTYLINDOLES ET ANALOGUES EN TANT QU'INHIBITEURS DE TOLÉRANCE AUX ANTIBIOTIQUES
  申请人：SPERO THERAPEUTICS INC

  公开号：WO2016112088A1

  公开（公告）日：2016-07-14

  The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

  该披露提供了芳基氧乙酰基吲哚化合物及类似物的化合物和药物组合物，用于治疗慢性和急性细菌感染。其中某些化合物是一般式(I)（I）的化合物或其药用可接受的盐或前药。该披露的某些化合物是MvfR抑制剂。MvfR抑制剂减少抗生素耐药细菌菌株的形成，对治疗革兰氏阴性细菌感染和减少铜绿假单胞菌的毒力有用。该披露还提供了治疗受试者细菌感染的方法，包括铜绿假单胞菌感染。
• Nitric oxide enhancing diuretic compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20060189603A1

  公开（公告）日：2006-08-24

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  该发明描述了包含至少一种增强一氧化氮利尿化合物或其药用盐的新型组合物和试剂盒，以及可选地，至少一种增强一氧化氮化合物和/或至少一种治疗剂的试剂盒。该发明还提供了以下方法：(a)治疗由过多水分和/或电解贮留引起的症状；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)高脂血症。增强一氧化氮利尿化合物包括至少一种增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点与利尿化合物连接，连接通过不能水解的键或基团。
• Synthesis of Medium Ring Ethers. 5. The Synthesis of (+)-Laurencin
  作者：Jonathan W. Burton、J. Stephen Clark、Sam Derrer、Thomas C. Stork、Justin G. Bendall、Andrew B. Holmes

  DOI：10.1021/ja9709132

  日期：1997.8.1

  enantioselective synthesis of (+)-laurencin 1 has been achieved in 27 steps from (R)-malic acid 20. The key steps involved methylenation of the lactone 49 followed by intramolecular hydrosilation of the enol ether 14 (Scheme 11) and one carbon homologation of the diol 13 to give the key ethyl substituted cyclic ether 59 (Scheme 13). The lactone 49 was obtained by two efficient routes, namely a Claisen ring expansion

  (+)-月桂酸 1 的对映选择性合成已在 (R)-苹果酸 20 的 27 个步骤中实现。关键步骤包括内酯 49 的亚甲基化，然后是烯醇醚 14（方案 11）和一个碳的分子内氢化硅烷化二醇13的同系化得到关键的乙基取代的环醚59（方案13）。内酯 49 是通过两种有效途径获得的，即克莱森环扩张（方案 3），然后是 α-羟基化（方案 6）和山口内酯化（方案 11）。(E)-戊烯炔基侧链的精心设计（方案18）和溴的引入（方案19）完成了（+）-月桂酸1的合成。
• Total synthesis of (+)-laurencin
  作者：Kazunori Tsushima、Akio Murai

  DOI：10.1016/s0040-4039(00)74256-0

  日期：1992.7

  The first total synthesis of (+)-laurencin (1), which is the most representative marine natural product isolated from red algae, is described via intermediates 2–18. Key steps in the synthesis include a facile oxidative preparation of 2, an effective conversion of 9a to 11, and a SmI2-catalyzed elongation reaction of 15, providing 16a.

  经由中间体2–18描述了（+）-laurencin（1）的首次总合成，这是从红藻中分离出来的最具代表性的海洋天然产物。在合成关键步骤包括的容易氧化制备2，一种有效的转换图9A到11，和一个SMI 2的催化的延伸反应15，提供了图16A。
• NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：GARVEY David S.

  公开号：US20080255101A1

  公开（公告）日：2008-10-16

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  这项发明描述了新颖的组合物和试剂盒，包括至少一种增强一氧化氮利尿化合物或其药学上可接受的盐，并且可选地，还包括至少一种增强一氧化氮化合物和/或至少一种治疗剂。该发明还提供了以下方法：(a)治疗由过度水和/或电解质潴留引起的疾病；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗先兆子痫；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)治疗高脂血症。增强一氧化氮利尿化合物包括至少一个增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点连接到利尿化合物上，通过无法水解的键或基团连接。